Novosteo Inc. father and son co-founders Philip Low and Stewart Low are developing and commercializing a targeted drug combination that, when injected, is shown to expedite bone fracture healing.
CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results